Patient history and symptoms
Pre-test probability
RA specific serology testing (e.g., CCP, RF IgM, RF IgA)
Post-test probability to narrow differential
If appropriate, referral to rheumatology for further evaluation
Further evaluation
Accurate diagnosis
Patient history and symptoms
Pretest probability
RA specific serology testing (e.g., CCP, RF IgM, RF IgA)
Post-test probability to narrow differential
If appropriate, referral to rheumatology for further evaluation
Further evaluation
Accurate diagnosis
CCP is a clinically specific marker to support in the diagnosis of RA, and its specificity for RA reduces false positive results.7
75% of initial RA testing in primary care does not include CCP. 11
Use of CCP assays helps increase the postive predictive value for testing. 5
Combining EliATM RF IgM and EliATM RF IgA in laboratory analysis is vital in helping identify and quickly manage RA.
Less than 5% of non-RA patients are positive for both RF IgM and IgA.12
These are isotype-specific, which provides added value compared to total RF assays based on agglutination (e.g. nephelometric or turbidimetric RF assays). 12,13
Balance of specificity and sensitivity
Antigens used in EliA™ assays are manufactured using innovative recombinant protein technology, which optimizes accessibility and purity, aiding clinicians in making impactful and appropriate decisions.16-18
High quality assays, aiding in antibody identification16-18
Even for difficult-to-detect antibodies highquality EliA™ antigens can help identify important antibodies associated with RA.5
Less false positives
THigh specificity due to the selection and use of recombinant antigens in this portfolio means laboratories can help reduce the number of false positives, aiding clinicians in prescribing appropriate therapies.16